Literature DB >> 22743155

Long-term follow-up of pain and emotional characteristics of women after surgery for breast cancer.

David Sheridan1, Irwin Foo, Halia O'Shea, David Gillanders, Linda Williams, Marie Fallon, Lesley Colvin.   

Abstract

CONTEXT: Persistent pain after treatment for breast cancer (PPBCT) is a common side effect of breast cancer treatment, with prevalence as high as 50%. It is predominantly a neuropathic condition.
OBJECTIVES: The aim of this cross-sectional, questionnaire-based study was to examine the emotional characteristics of patients with PPBCT in long-term breast cancer patients. A secondary objective was to characterize the risk factors and severity of that pain.
METHODS: From March 1, 2010 to April 9, 2010, long-term follow-up patients were invited to complete a questionnaire. This recorded their surgical and demographic data and ascertained whether they had PPBCT. If the patient had pain, she completed a range of validated self-report questionnaires and questions about the nature of the pain, including a visual analogue scale.
RESULTS: One hundred eleven patients completed the questionnaire; 33 (29.7%) patients reported chronic pain at a median time of 64 months postoperatively (interquartile range 54.25). Patients with persistent pain were not significantly more anxious (t(105)=-0.369, P=0.713) or depressed (t(105)=0.713, P=0.507) than patients without pain. Patients with constant pain compared with intermittent pain were significantly more anxious (t(25)=-3.460, P=0.002). Preoperative pain conferred a fivefold increased risk of PPBCT (odds ratio [OR]=5.17, 95% confidence interval [CI]=1.79-14.97, P=0.002); chemotherapy conferred a threefold increased risk (OR=3.004, 95% CI=1.22-7.40, P=0.017).
CONCLUSION: We have shown significant numbers of patients suffer from PPBCT. At a median time of 64.5 months, women with pain are not significantly more anxious or depressed than women without pain. Preoperative pain and chemotherapy have been highlighted as risk factors.
Copyright © 2012 U.S. Cancer Pain Relief Committee. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22743155     DOI: 10.1016/j.jpainsymman.2011.10.021

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  13 in total

1.  Persistent Breast Pain Among Women With Histories of Breast-conserving Surgery for Breast Cancer Compared With Women Without Histories of Breast Surgery or Cancer.

Authors:  Sara N Edmond; Rebecca A Shelby; Francis J Keefe; Hannah M Fisher; John E Schmidt; Mary S Soo; Celette S Skinner; Gretchen M Ahrendt; Jessica Manculich; Jules H Sumkin; Margarita L Zuley; Dana H Bovbjerg
Journal:  Clin J Pain       Date:  2017-01       Impact factor: 3.442

2.  Social support predicts inflammation, pain, and depressive symptoms: longitudinal relationships among breast cancer survivors.

Authors:  Spenser Hughes; Lisa M Jaremka; Catherine M Alfano; Ronald Glaser; Stephen P Povoski; Adele M Lipari; Doreen M Agnese; William B Farrar; Lisa D Yee; William E Carson; William B Malarkey; Janice K Kiecolt-Glaser
Journal:  Psychoneuroendocrinology       Date:  2014-01-05       Impact factor: 4.905

Review 3.  Cancer treatment-related neuropathic pain syndromes--epidemiology and treatment: an update.

Authors:  Ellen M Lavoie Smith; Celia M Bridges; Grace Kanzawa; Robert Knoerl; James P Kelly; Anna Berezovsky; Charis Woo
Journal:  Curr Pain Headache Rep       Date:  2014-11

4.  Distress Disorder Histories Relate to Greater Physical Symptoms Among Breast Cancer Patients and Survivors: Findings Across the Cancer Trajectory.

Authors:  Megan E Renna; M Rosie Shrout; Annelise A Madison; Maryam Lustberg; Stephen P Povoski; Doreen M Agnese; Raquel E Reinbolt; Robert Wesolowski; Nicole O Williams; Bhuvaneswari Ramaswamy; Sagar D Sardesai; Anne M Noonan; Jeffrey B VanDeusen; Daniel G Stover; Mathew Cherian; William B Malarkey; Michael Di Gregorio; Janice K Kiecolt-Glaser
Journal:  Int J Behav Med       Date:  2022-07-13

5.  Associations between cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression in patients prior to breast cancer surgery.

Authors:  Sy-Huey Doong; Anand Dhruva; Laura B Dunn; Claudia West; Steven M Paul; Bruce A Cooper; Charles Elboim; Gary Abrams; John D Merriman; Dale J Langford; Heather Leutwyler; Christina Baggott; Kord Kober; Bradley E Aouizerat; Christine Miaskowski
Journal:  Biol Res Nurs       Date:  2014-10-10       Impact factor: 2.522

6.  Persistent breast pain 5 years after treatment of invasive breast cancer is largely unexplained by factors associated with treatment.

Authors:  Robin J Bell; Penelope J Robinson; Fathima Nazeem; Mary Panjari; Pamela Fradkin; Max Schwarz; Susan R Davis
Journal:  J Cancer Surviv       Date:  2013-08-23       Impact factor: 4.442

7.  Worry and rumination in breast cancer patients: perseveration worsens self-rated health.

Authors:  Megan E Renna; M Rosie Shrout; Annelise A Madison; Maryam Lustberg; Stephen P Povoski; Doreen M Agnese; Raquel E Reinbolt; Robert Wesolowski; Nicole O Williams; Bhuvaneswari Ramaswamy; Sagar D Sardesai; Anne M Noonan; Jeffrey B VanDeusen; William B Malarkey; Janice K Kiecolt-Glaser
Journal:  J Behav Med       Date:  2020-11-01

Review 8.  Treatment related impairments in arm and shoulder in patients with breast cancer: a systematic review.

Authors:  Janine T Hidding; Carien H G Beurskens; Philip J van der Wees; Hanneke W M van Laarhoven; Maria W G Nijhuis-van der Sanden
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

9.  Persistent depressive symptoms and pain after cardiac surgery.

Authors:  Lynn V Doering; Belinda Chen; Anthony McGuire; Rebecca Cross Bodán; Michael R Irwin
Journal:  Psychosom Med       Date:  2014 Jul-Aug       Impact factor: 4.312

10.  Cancer treatment-related neuropathic pain: proof of concept study with menthol--a TRPM8 agonist.

Authors:  M T Fallon; D J Storey; A Krishan; C J Weir; R Mitchell; S M Fleetwood-Walker; A C Scott; L A Colvin
Journal:  Support Care Cancer       Date:  2015-02-15       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.